This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

This information is intended for healthcare professionals based in Ireland. If you are not a healthcare professional in Ireland, click here

Overview patient checklist

ELIQUIS® (apixaban) Resources for Healthcare Professionals

Checklist to use when prescribing ELIQUIS to patients with NVAF

Checklist to use when prescribing ELIQUIS to patients with DVT / PE

Checklist to use when prescribing ELIQUIS to patients with NVAF switching from warfarin

ELIQUIS® (apixaban): an oral, direct factor Xa inhibitor — is indicated for:

  • Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II)1
  • Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults1
  • Prevention of Venous Thromboembolic Event (VTE) in adult patients who have undergone elective hip or knee replacement surgery1

ELIQUIS (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of VTE in adult patients who have undergone elective hip or knee replacement surgery.1

Footnotes:

  • DVT = Deep Vein Thrombosis   NVAF = Non-Valvular Atrial Fibrillation   NYHA = new York Heart Association   PE = Pulmonary Embolism   TIA = Transient Ischaemic Attack   VTE = Venous Thromboembolic Event

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.

Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie

Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com